QIAGEN completed the acquisition of Parse Biosciences.

QIAGEN, a global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights, completed the acquisition of Parse Biosciences, a provider of scalable, chemistry-based single-cell solutions. Financial terms were not disclosed. “Parse was founded to make single-cell sequencing accessible to any lab. As our team joins QIAGEN, we want to accelerate that mission and extend the reach of our technology to more customers around the world. QIAGEN’s strong commitment to Sample technologies and its global infrastructure make it an ideal partner for our next stage of growth, ” Alex Rosenberg, PhD, Parse Biosciences CEO and co-founder.